Instinct Bio Completes Business Combination with Relativity Acquisition Corp. and Makes Its Nasdaq Debut Under the Ticker “BIOT” on July 24, 2026

Instinct Bio’s Nasdaq debut is all hype, no financial substance for investors yet.

What the company is saying

Instinct Bio is positioning itself as a rare, vertically integrated, revenue-generating health and longevity platform now accessible to U.S. public market investors. The company’s core narrative is that it unites proprietary stem cell technology, in-house manufacturing, and premium consumer brands, offering a differentiated combination of real products, diversified revenue, and a deep innovation pipeline. Management claims that the global longevity and wellness market is set for explosive growth—from $27.6 billion in 2025 to $67.0 billion by 2035—and frames Instinct Bio as ideally placed to capture this opportunity. The announcement emphasizes the successful completion of the business combination with Relativity Acquisition Corp., the upcoming Nasdaq debut under the ticker “BIOT,” and a pro forma enterprise value of $288 million. It also highlights ambitious plans to scale manufacturing, accelerate product rollouts, and expand internationally, particularly across Asia. However, the release buries or omits any mention of actual revenue, profit, cash flow, or operational milestones, providing no hard evidence for its claims of vertical integration or commercial traction. The tone is highly positive and aspirational, projecting confidence and momentum, but it is not backed by concrete financial or operational data. Notable individuals named include Tomoki Nagano, Chairman and CEO of Instinct Bio, and Tarek K. Tabsh, CEO of Relativity Acquisition Corp.; their roles are significant in that they are the principal architects of the transaction, but there is no evidence of outside institutional investment or endorsement. This narrative fits a classic post-SPAC listing investor relations strategy: maximize excitement around the listing and sector growth, while deferring hard questions about financial performance and execution.

What the data suggests

The only hard number disclosed is the pro forma enterprise value of approximately $288 million at closing, which reflects the transactional valuation agreed upon for the business combination, not operational performance. There are no revenue, EBITDA, net income, or cash flow figures provided for Instinct Bio—no quarterly or annual financial statements, no period-over-period trends, and no guidance. The announcement does not disclose whether Instinct Bio is profitable, cash-flow positive, or even generating meaningful revenue, despite claims of being a 'revenue-generating' platform. There is also no information on customer numbers, product sales, or market share, making it impossible to assess the company’s actual commercial footprint. The gap between what is claimed—differentiated products, diversified revenue, and innovation—and what is evidenced is vast; none of the operational claims are substantiated by data. No prior targets or guidance are referenced, and there is no indication of whether any internal or external benchmarks have been met. The quality of financial disclosure is poor: key metrics are missing, and the only quantitative data point is a deal valuation, not a measure of business health. An independent analyst reviewing this announcement would conclude that, aside from the fact of the listing and the enterprise value, there is no basis to evaluate Instinct Bio’s financial trajectory or operational credibility.

Analysis

The announcement's tone is notably positive, emphasizing the completion of the business combination and the upcoming Nasdaq debut. However, the majority of substantive claims about Instinct Bio's business model, market opportunity, and future growth are forward-looking and aspirational, with little to no supporting operational or financial data. The only concrete, realised milestone is the transaction closing and listing, with a pro forma enterprise value disclosed. There is no disclosure of revenue, profit, or cash flow, and no evidence is provided for claims of vertical integration, proprietary technology, or diversified revenue. The narrative inflates the company's profile by referencing sector growth projections and ambitious expansion plans, but these are not substantiated by measurable progress or binding agreements beyond the listing itself. The capital intensity flag is triggered by the $288 million enterprise value and the absence of immediate earnings impact or profitability data.

Risk flags

• ●Operational risk is high because the company provides no evidence of current revenue, profitability, or customer traction. Without these metrics, investors cannot assess whether the business model is viable or scalable.
• ●Financial disclosure risk is acute: the announcement omits all key financial statements, including revenue, EBITDA, net income, and cash flow. This lack of transparency makes it impossible to evaluate the company’s financial health or trajectory.
• ●Execution risk is substantial, as the majority of claims are forward-looking and aspirational, with no disclosed timelines, binding agreements, or interim milestones. The company’s ability to deliver on its promises is unproven.
• ●Capital intensity risk is flagged by the $288 million enterprise value, which implies significant capital requirements for manufacturing, R&D, and international expansion. If the company is not already generating cash, future dilution or debt is likely.
• ●Disclosure pattern risk is evident: the announcement relies heavily on sector growth projections and broad claims about technology and integration, but provides no company-specific evidence. This pattern is typical of hype-driven SPAC listings.
• ●Timeline risk is high because the projected benefits—such as capturing a share of a rapidly growing market—are long-term and speculative. Investors face a multi-year wait before any claims can be validated.
• ●Geographic risk is present, as the company is headquartered in Japan but is listing in the U.S. and claims a commercial footprint across Asia. Cross-border regulatory, operational, and market-entry challenges could impede execution.
• ●Leadership risk is moderate: while the named executives are responsible for the transaction, there is no evidence of outside institutional investment or endorsement, which would provide additional validation. The absence of such backing means investors are relying solely on management’s narrative.

Bottom line

For investors, this announcement is primarily a transactional milestone: Instinct Bio is now a publicly traded company on Nasdaq under the ticker BIOT, following its business combination with Relativity Acquisition Corp. Beyond the listing and the $288 million enterprise value, there is no substantive financial or operational information provided. The company’s narrative is ambitious and paints a picture of a high-growth, innovative platform, but none of these claims are supported by hard data—no revenue, no profit, no customer numbers, and no evidence of commercial traction. The involvement of Tomoki Nagano and Tarek K. Tabsh is notable only in their roles as company and SPAC CEOs; there is no indication of institutional investment or third-party validation. To change this assessment, the company would need to disclose actual financial results—revenue, profitability, cash flow—and provide evidence of product sales, customer adoption, and binding commercial agreements. In the next reporting period, investors should watch for audited financial statements, revenue breakdowns, and concrete operational milestones such as signed partnerships or product launches. At this stage, the announcement is not actionable from an investment perspective; it is a signal to monitor, not to act on. The most important takeaway is that Instinct Bio’s public debut is all sizzle and no steak—until the company provides real financial and operational evidence, investors should remain on the sidelines.

Announcement summary

(NASDAQ: BIOT) Instinct Bio Technical Company Holdings Inc. completed its previously announced business combination with Relativity Acquisition Corp. (OTC: ACQC), resulting in Instinct Bio's Nasdaq debut under the ticker “BIOT” on July 24, 2026. The pro forma enterprise value at closing was approximately $288 million. Instinct Bio’s common stock and warrants are expected to commence trading on the Nasdaq Stock Market under the ticker symbols “BIOT” and “BIOTW”, respectively, beginning July 24, 2026. The global longevity and wellness market is projected to grow from approximately $27.6 billion in 2025 to approximately $67.0 billion by 2035. Instinct Bio is headquartered in Tokyo, Japan, with operations spanning Tokyo, Las Vegas, and New York, and an established commercial footprint across Asia. The company unites proprietary stem cell technology, in-house manufacturing, and premium consumer brands under one roof. The company projects to scale vertically integrated manufacturing capacity and accelerate the rollout of premium regenerative health and skincare products across new channels and geographies.

Disagree with this article?